Technical Analysis for TYRA - Tyra Biosciences, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Resistance | Bearish | 0.00% | |
| 200 DMA Support | Bullish | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Fell Below 20 DMA | Bearish | -5.56% | |
| Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | -5.56% | |
| Inside Day | Range Contraction | -5.56% | |
| Crossed Above 20 DMA | Bullish | -7.75% | |
| MACD Bullish Signal Line Cross | Bullish | -7.75% | |
| Wide Range Bar | Range Expansion | -7.75% | |
| Up 3 Days in a Row | Strength | -7.75% |
| Alert | Time |
|---|---|
| 200 DMA Support | about 19 hours ago |
| 60 Minute Opening Range Breakdown | about 19 hours ago |
| Fell Below 10 DMA | about 20 hours ago |
| 10 DMA Support | about 21 hours ago |
| Down 5% | about 21 hours ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/02/2024
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company, focuses on developing therapies to overcome tumor resistance and enhance outcomes for patients with cancer. Its lead product candidate is TYRA-300, a selective inhibitor of fibroblast growth factor receptor (FGFR)3 for the treatment of muscle invasive bladder cancer. The company is also developing programs targeting FGFR2-related cancers, FGFR3-related achondroplasia, REarranged during transfection kinase, and FGFR4-related cancers. Tyra Biosciences, Inc. was incorporated in 2018 and is headquartered in Carlsbad, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Biology Tumor Cell Biology Tyrosine Kinase Receptors Bladder Cancer Fibroblast Growth Factor Fibroblast Growth Factor Receptor Preclinical Stage Biopharmaceutical Clusters Of Differentiation
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Cancer Biology Tumor Cell Biology Tyrosine Kinase Receptors Bladder Cancer Fibroblast Growth Factor Fibroblast Growth Factor Receptor Preclinical Stage Biopharmaceutical Clusters Of Differentiation
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 20.67 |
| 52 Week Low | 10.47 |
| Average Volume | 129,337 |
| 200-Day Moving Average | 14.81 |
| 50-Day Moving Average | 17.50 |
| 20-Day Moving Average | 15.98 |
| 10-Day Moving Average | 15.14 |
| Average True Range | 0.94 |
| RSI (14) | 41.18 |
| ADX | 21.86 |
| +DI | 26.46 |
| -DI | 27.47 |
| Chandelier Exit (Long, 3 ATRs) | 15.43 |
| Chandelier Exit (Short, 3 ATRs) | 16.94 |
| Upper Bollinger Bands | 18.29 |
| Lower Bollinger Band | 13.67 |
| Percent B (%b) | 0.31 |
| BandWidth | 28.93 |
| MACD Line | -0.52 |
| MACD Signal Line | -0.59 |
| MACD Histogram | 0.0675 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 17.15 | ||||
| Resistance 3 (R3) | 17.27 | 16.71 | 16.81 | ||
| Resistance 2 (R2) | 16.71 | 16.19 | 16.65 | 16.70 | |
| Resistance 1 (R1) | 15.91 | 15.87 | 15.63 | 15.79 | 16.58 |
| Pivot Point | 15.35 | 15.35 | 15.21 | 15.29 | 15.35 |
| Support 1 (S1) | 14.55 | 14.83 | 14.27 | 14.43 | 13.64 |
| Support 2 (S2) | 13.99 | 14.51 | 13.93 | 13.52 | |
| Support 3 (S3) | 13.19 | 13.99 | 13.41 | ||
| Support 4 (S4) | 13.07 |
